Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advances study found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://vasilievichx543cxt7.shoutmyblog.com/profile